Colorectal Cancer Market

The global Colorectal Cancer Market is valued at USD 12.5 Billion in 2024 and is projected to reach a value of USD 13.1 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 4.8% between 2025 and 2035.

Key highlights of Colorectal Cancer Market

• The North American continent dominated the market in 2024, obtaining the largest revenue share of 46.2%
• The Asia Pacific region will witness remarkable growth with a CAGR during the forecast period
• In 2024, the Immunotherapy segment from the segmentation of the Therapy, dominated the Colorectal Cancer market with significant market share of 50.1%
• The Colorectal Adenocarcinoma segment from the Cancer Type segmentation, dominated the market with 46.2% market share in 2024
• In 2024, from among the segmentation of the Distribution Channel, the Hospital Pharmacies segment dominated the market with 44.6% market share
• Advancements in medical technologies and diagnostic tools have led to earlier detection of colorectal cancer, enabling prompt intervention and improving patient outcomes drives the Colorectal Cancer market

Colorectal Cancer Market: Regional Overview

North America Dominated Sales with a 31.5% share in 2024. The regions well-established healthcare infrastructure and high prevalence of colorectal cancer play a significant role in market growth. Advanced health care systems identify issues early and treat patients effectively, which improves patient outcomes and will increase the market for novel remedies. Leading pharmaceutical agencies and educational institutions are also heavily focused in the region, which facilitates to expedite the improvement and advertising and marketing of innovative treatments such as immunotherapies and targeted therapies.

​Favorable regulatory environments and substantial government funding further bolster market in North America. in order to make sure that novel remedies are directly administered to patients, regulatory organizations including the FDA accelerate the evaluation strategies for breakthrough therapies. For instance, the oral targeted treatment FRUZAQLA (fruquintinib) developed by Takeda was approved by the US FDA in November 2023 for use in adults with metastatic colorectal cancer (mCRC).

The integration of technologies, such telemedicine and digital health tools, is essential to enhancing patient care and access. The introduction of new products and strategic alliances amongst top companies also encourage market growth. For instance, in April 2020, the FDA approved Pfizers cancer drug Braftovi (encorafenib) in combination with Eli Lillys EGFR antagonist, Erbitux (cetuximab), for treating patients with BRAFV600E-mutated metastatic colorectal cancer after previous therapy.

U.S. Colorectal Cancer Market Overview

The U.S. Colorectal Cancer market, valued at USD 3.4 Billion in 2024 to USD 5.23 Billion in 2035

Colorectal Cancer Market: Therapy Overview

The Immunotherapy segment dominated the Colorectal Cancer market with the largest share of 50.1% in 2024. The Colorectal Cancer market, segmented by the Therapy, is bifurcated into Targeted Therapy, Immunotherapy, Chemotherapy and Others.

Immunotherapy dominance is largely attributed to the increasing adoption of immune checkpoint inhibitors like pembrolizumab and nivolumab. Immunotherapy has remarkable efficacy in treating patients with specific genetic profiles, such as those with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors. Immunotherapy leads to improved patient outcomes and prolonged survival rates by improving the bodys immune response against cancer cells.

The immunotherapys growth is further driven by ongoing research and clinical trials exploring novel combinations and new therapeutic targets. Combining immune checkpoint inhibitors with different treatments, such as chemotherapy or targeted therapies, has shown promise in overcoming resistance and enhancing therapeutic effectiveness. For instance, in December 2023, Moderna Inc. and Merck, known as MSD outside of the United States and Canada, have announced promising follow-up data from their Phase 2b study of mRNA-4157 (V940) in combination with Mercks KEYTRUDA (pembrolizumab) therapy.

Additionally, improvements in biomarker identity allow more precise patient stratification, ensuring that those most likely to advantage from immunotherapy receive the appropriate treatment. The growing prominence of immunotherapy in the Colorectal Cancer market displays a broader shift in the direction of revolutionary, customized medicinal drug.

Colorectal Cancer Market: Government Initiatives

• The Ohio Colorectal Cancer Prevention Initiative (OCCPI), led by Heather Hampel, MS, LGC, is a statewide program focused on screening newly diagnosed colorectal cancer (CRC) patients and their biological relatives for Lynch syndrome. Funded by Pelotonia, the initiative aims to identify family members at risk so they can take preventive measures.
• The National Strategic Plan for Colorectal Cancer (NSPCRC) 2021-2025 aligns with the National Strategic Plan for Cancer Control Programme (NSPCCP) 2021-2025. Developed by a technical working group of diverse professionals starting in August 2020, the plan involved a series of meetings and workshops.
• In August 2023, the U.S. FDA granted approval to Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc. for LONSURF (trifluridine/tipiracil) as a treatment option for adult patients diagnosed with metastatic colorectal cancer (mCRC). LONSURF can be administered either as a single agent or in combination with bevacizumab.
• In 2023, Indias hospital network launched a life-saving colon cancer trial, with twelve hospitals across the country participating to support the trial. The FOxTROT-Global trial, funded by Cancer Research UK and supported by the Universities of Birmingham and Leeds, is conducted in parallel with the ongoing FOxTROT2 trial in the UK and France.

Key Trends

• There is a growing trend towards personalized medicine in colorectal cancer treatment by tailoring therapies based on individual genetic profiles. Targeted therapies are becoming more and more common; they target particular genetic mutations and biological targets. Compared to conventional chemotherapy, these treatments offer lower adverse effects and increased efficacy.
• The shift towards liquid biopsies, which involve analyzing circulating tumor DNA (ctDNA) in blood samples, are emerging as a non-invasive method for early detection, monitoring treatment response, and detecting minimal residual disease. Businesses are setting the standard for the development of new technologies, which could result in more individualized treatment regimens and earlier diagnoses.
• The adoption of telemedicine and digital health solutions has accelerated and make it easier to follow treatment plans, monitor patients continuously, and conduct remote consultations. Telemedicine offers frequent contact between patients and healthcare providers, which also improves access to care for patients living in rural places.

Premium Insights

The Colorectal Cancer market is driven by the increasing prevalence of colorectal cancer globally, with rising incidence rates observed in various regions. For instance, according to WHO, Colorectal cancer ranks as the third most prevalent cancer globally, comprising around 10% of all cancer cases, and stands as the second leading cause of cancer-related mortality worldwide. Primarily affecting older individuals, the majority of colorectal cancer cases arise in individuals aged 50 and above. The increasing incidence of colorectal cancer is due to a number of variables, such as aging populations, sedentary lifestyles, and dietary habits which result in more remedy options and interventions are required.

The Colorectal Cancer market is characterized by ongoing R&D activities aimed at introducing innovative therapies and treatment modalities. The emergence of precision medicine and targeted medications, which offer tailored remedy regimens depending on patient profiles, is a noteworthy development in the field. With the promising effects of immunotherapies, which include immune checkpoint inhibitors, inside the treatment of colorectal cancer, the therapeutic landscape is turning into even more varied. furthermore, through partnerships and strategic alliances that assist market expansion, pharmaceutical companies and research institutions can discover and commercialize modern treatments.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Timely regulatory approvals are a crucial driver in the Colorectal Cancer market

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a pivotal role in determining how quickly new treatments can reach patients. When these bodies provide expedited reviews and fast-track designations, they significantly shorten the time required for promising therapies to move from development to market. This expedited process not only benefits patients by providing earlier access to potentially life-saving treatments but also enhances the competitive edge of pharmaceutical companies. The faster approval timelines encourage more research and investment into new colorectal cancer treatments, as companies are more confident in their ability to recoup development costs and generate profits. Moreover, successful regulatory approvals often set a precedent that can influence future submissions, streamlining the process for subsequent drugs. This momentum can lead to a continuous influx of innovative treatments entering the market, thus driving overall market growth and enhancing patient outcomes.

High development costs present a significant barrier in the Colorectal Cancer market

Developing a new drug from initial research through to commercialization typically involves substantial financial investment. Costs encompass early-stage research, preclinical testing, multiple phases of clinical trials, manufacturing, and marketing. Clinical trials alone are particularly expensive, often requiring the recruitment of large patient cohorts, extended durations, and complex logistical arrangements to ensure compliance with stringent regulatory standards. These financial burdens are further exacerbated by the high risk associated with drug development. A large proportion of investigational drugs fail to make it through the clinical trial phases, resulting in sunk costs with no return on investment. The high development costs can deter smaller biotech firms from entering the market, as they may lack the necessary resources to sustain lengthy and costly development processes. This restraint can limit the diversity of the market, potentially slowing the rate of innovation and reducing the availability of novel therapies for patients.

Competitive Landscape

The competitive landscape of the Colorectal Cancer market is characterized by a robust mix of established pharmaceutical giants and innovative biotechnology firms, each striving to advance the standards of care through novel therapeutics and diagnostics. Key players like Roche, Merck, and Pfizer dominate with their extensive portfolios and ongoing clinical trials, while emerging companies like Guardant Health and Natera are pioneering in liquid biopsy and early detection technologies. The market is highly dynamic, driven by the continuous development of targeted therapies, immunotherapies, and personalized medicine approaches. Strategic partnerships, mergers, and acquisitions are frequent, as companies seek to enhance their pipelines and market reach. The competitive environment is also shaped by the varying regulatory landscapes across different regions, influencing the speed and nature of product approvals and market entry strategies.

The key players in the global Colorectal Cancer market include - Eli Lilly and Company (U.S.) among others.

Recent Market Developments

• In April 2023, Eisai, headquartered in Japan, is advancing the Phase III clinical development of Lenvatinib Mesylate for the treatment of colorectal cancer, with progress noted.
• In January 2024, Merck and Inspirna, Inc. (New York, NY) announced a licensing agreement for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and subsequent medications that target SLC6A8. Omepenaclid is now being investigated as a potential second-line treatment for metastatic or advanced RAS-mutant colorectal cancer (mCRC) in Phase II studies.
• In June 2023, Bevacizumab, a less expensive medication from Enzene Biosciences, is now available for the treatment of metastatic colorectal cancer. It is a biosimilar drug that can replace Avastin, which is more costly.

The global Colorectal Cancer market can be categorized as Therapy, Cancer Type, Distribution Channel, and Region.